Comparison of two doses of aspirin for preventing blood clots after hip and knee replacement surgery

A Randomized Controlled Trial Comparing the Efficacy and Safety of Aspirin 75 mg vs. Aspirin 150 mg for Venous Thromboembolism (VTE) Prophylaxis in Patients Undergoing Total Hip and Knee Arthroplasty

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091707

Enrollment

3000

Registered

2025-07-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M16- Osteoarthritis of hip Health Condition 2: M17- Osteoarthritis of knee

Interventions

Intervention1: Aspirin 75 mg: Aspirin 75 mg tablet, administered orally once daily for 4 weeks postoperatively for VTE prophylaxis in patients undergoing total hip and knee arthroplasty. Control Inter

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults undergoing primary total hip or knee arthroplasty 2. No prior history of DVT or VTE 3. Willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Active bleeding disorders or peptic ulcer disease 2. History of stroke, recent myocardial infarction (MI), or severe renal or liver dysfunction 3. Patients on chronic anticoagulant therapy 4. Patients undergoing partial hip or knee replacement

Design outcomes

Primary

Measure	Time frame
Incidence of symptomatic venous thromboembolism (VTE) within 90 days postoperativelyTimepoint: Incidence of symptomatic venous thromboembolism (VTE) within 90 days postoperatively	—

Secondary

Measure	Time frame
1. Incidence of major, minor bleeding eventsTimepoint: At baseline, 4 weeks, 12 weeks;2.Rate of early periprosthetic joint infectionTimepoint: At baseline, 4 weeks, 12 weeks;3. Gastrointestinal complications ,all couse mortalityTimepoint: At baseline, 4 weeks, 12 weeks	—

Countries

India

Contacts

Public ContactSahil Sanghavi

Sancheti Institute for Orthopedics and Rehabilitation

sahil.sanghavi@hotmail.com9921522220

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026